Revolution Medicines, Inc.
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
Last updated:
Abstract:
The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
Status:
Application
Type:
Utility
Filling date:
28 Oct 2020
Issue date:
4 Nov 2021